What factors determine patients’ preference for tumour necrosis factor inhibitors in ankylosing spondylitis? |
| |
| Authors: | Dessy W Fajri Caroline A Brand Shyamali C Dharmage Belinda J Martin Russell R C Buchanan Lionel Schachna |
| |
| Institution: | (1) Department of Rheumatology, Austin Health, Heidelberg, Victoria, Australia;(2) Clinical Epidemiology and Health Services Evaluation Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia;(3) The Centre for Research Excellence in Patient Safety, Monash University, Prahran, Victoria, Australia;(4) Centre for MEGA Epidemiology, Melbourne School of Population Health, University of Melbourne, Carlton, Victoria, Australia;(5) Austin Spondylitis Clinic, Austin Health, P.O. Box 5555, Heidelberg, Victoria, 3084, Australia; |
| |
| Abstract: | Tumour necrosis factor inhibitor (TNFi) therapy, either intravenous (IV) or subcutaneous (SQ), demonstrates similar efficacy
in ankylosing spondylitis (AS). The objective of this study was to examine factors influencing patient preference of TNFi.
Fifty-nine (79.7%) participants were male with mean age 43.9 years and disease duration of 22.0 years. Fifty-nine patients
(79.7%) agreed with the statement ‘My doctor gave me a choice and I made a decision based on my personal preference’. Patients
commenced first on IV TNFi most commonly cited reduced frequency of injections (96.6%), administration by a trained professional
(89.7%) and use of infusion time for leisure activities (86.2%). Patients commenced on SQ TNFi cited flexibility with timing
of treatment (80%), shortened administration time (73.3%) and the convenience of home therapy (73.3%). Shared clinical decision-making
between clinicians and patients may be desirable for AS patients commencing TNFi therapy. |
| |
| Keywords: | Ankylosing spondylitis Choice Determinants Intravenous Preference Subcutaneous Tumour necrosis factor inhibitor |
| 本文献已被 SpringerLink 等数据库收录！ |
|
